<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427373</url>
  </required_header>
  <id_info>
    <org_study_id>2013-10701</org_study_id>
    <nct_id>NCT02427373</nct_id>
  </id_info>
  <brief_title>A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil</brief_title>
  <acronym>KOMPARE</acronym>
  <official_title>A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in&#xD;
      which 66 healthy adult subjects will receive 6 capsules/d, administered as a dose of 1.3 g/d&#xD;
      eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) in fish oil ethyl ester (EE), or fish&#xD;
      oil triglyceride (TG) or krill oil for a total of 4 weeks. The objective of the study is to&#xD;
      compare the oral bioavailability of EPA+DHA in total plasma across the three formulations at&#xD;
      the end of the 4 week study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of total plasma DHA+EPA levels across 3 treatment groups</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of RBC DHA+EPA levels across 3 treatment groups</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameter: AUC to 672hr</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameter: AUC to 336hr</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameter: Cmax</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameter: Tmax</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>fish oil ethyl ester</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fish oil triglyceride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>krill oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil ethyl ester</intervention_name>
    <arm_group_label>fish oil ethyl ester</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish oil triglyceride</intervention_name>
    <arm_group_label>fish oil triglyceride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>krill oil</intervention_name>
    <arm_group_label>krill oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy,&#xD;
&#xD;
          -  adult female who is neither pregnant nor breastfeeding, or&#xD;
&#xD;
          -  a healthy, adult male&#xD;
&#xD;
          -  with a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and&#xD;
&#xD;
          -  with a minimum weight of 50 kg (110 lbs).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history or presence of diabetes, high triglycerides (≥240 mg/dL), or high cholesterol&#xD;
             (≥240 mg/dL);&#xD;
&#xD;
          -  clinically significant abnormal finding on the physical exam, medical history, vital&#xD;
             signs, or clinical laboratory results at screening;&#xD;
&#xD;
          -  history or presence of allergic response to omega-3-fatty acids or sensitivity or&#xD;
             allergy to fish or shellfish;&#xD;
&#xD;
          -  history of coagulation disorder or current anticoagulation therapy;&#xD;
&#xD;
          -  has used any nutritional supplements, omega-3 supplements, fish oil, chia, krill oil,&#xD;
             flaxseed or foods supplemented with omega-3s within 3 months prior to the first dose&#xD;
             of study medication;&#xD;
&#xD;
          -  has used any prescription medication, except hormonal contraceptive or hormonal&#xD;
             replacement therapy, within 14 days prior to the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Smeberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>fish oil</keyword>
  <keyword>krill oil</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

